Lundbeck to present preclinical bexicaserin dual-mode data at European Epilepsy Congress
Lundbeck said preclinical data on bexicaserin’s dual mode of action will be featured in an oral presentation at the European Epilepsy Congress in Athens, Greece, 5–9 September.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.